INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 410s ago
House PTR10s ago
SEC 13F6h ago
Robinhood Chain6h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02SPSaba Capital Management, L.P.77B / 19S · 11 late96 trades$25.89M
  3. 03SJSheena Jonathan0B / 57S57 trades$3.61M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SLSpeiser Michael L0B / 35S35 trades$14.00M
  8. 08RARothblatt Martine A0B / 33S33 trades$5.50M
  9. 09RJRubinstein Julie0B / 32S32 trades$5.48M
  10. 10CECrimmins David Edward0B / 31S31 trades$723K

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

71,432 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
WL
Wang LingkeDirector, President
LIFEEthos Technologies Inc.
Derivative conversion
C—
64.0K sh
Jan 30, 2026Jan 30, 2026
Page 1373 of 1786
← PrevNext →
traded Jan 30, 2026
+0d
SEC Form 4

Evidence

9
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,859 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

9
MO
Moses Kelvin OChief Financial Officer
DOCHEALTHPEAK PROPERTIES, INC.
Grant or award
A—
36.8K sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

9
LP
Lawrence Steven PaulDirector, CEO
ASOAcademy Sports & Outdoors, Inc.
Tax withholding
F$46K
839 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

9
CG
Colis Peter GeorgeDirector, CEO and Secretary
LIFEEthos Technologies Inc.
Derivative conversion
C—
214.8K sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

9
HC
Hicks Ken CDirector
ASOAcademy Sports & Outdoors, Inc.
Option exercise
M—
1,245 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

9
FC
Ford Earl Carlton IVEVP & CFO
ASOAcademy Sports & Outdoors, Inc.
Option exercise
M—
499 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

9
PB
Patadia Ankit B.EVP and Treasurer
DOCHEALTHPEAK PROPERTIES, INC.
Grant or award
A—
1,079 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

9
Farquhar ScottDirector, 10% Owner
TEAMAtlassian Corp
Open-market sale · 10b5-1 plan
SELL$299K
2,501 sh
Jan 29, 2026Jan 30, 2026
traded Jan 29, 2026
+1dSEC Form 4

Evidence

9
CA
Caldwell Christopher ADirector, President and CEO
CNXCConcentrix Corp
Grant or award
A—
2,855 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

9
SJ
Sorbe Brian JamesPresident PTx
AGCOAGCO CORP /DE
Grant or award
A—
2,838 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

9
YN
York Charles N IICOO and CFO
DAWNDay One Biopharmaceuticals, Inc.
Grant or award
A—
188.0K sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

9
YN
York Charles N IICOO and CFO
DAWNDay One Biopharmaceuticals, Inc.
Grant or award
A—
126.0K sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

9
MO
Moses Kelvin OChief Financial Officer
DOCHEALTHPEAK PROPERTIES, INC.
Grant or award
A—
33.5K sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

9
BL
Barrett Victor LynnDirector
SMBKSMARTFINANCIAL INC.
Grant or award
A—
808 sh
Jan 29, 2026Jan 30, 2026
traded Jan 29, 2026
+1dSEC Form 4

Evidence

9
WL
Wang LingkeDirector, President
LIFEEthos Technologies Inc.
Derivative conversion
C—
291.5K sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

9
BR
Bohn Scott RCDO and Head of Lab
DOCHEALTHPEAK PROPERTIES, INC.
Grant or award
A—
2,396 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

9
WL
Wang LingkeDirector, President
LIFEEthos Technologies Inc.
Derivative conversion
C—
3.94M sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

9
AA
Alonso Lisa AEVP and Chief HR Officer
DOCHEALTHPEAK PROPERTIES, INC.
Tax withholding
F$4,463
252 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

9
WA
Wolpert Geoffrey AlanDirector
SMBKSMARTFINANCIAL INC.
Grant or award
A—
808 sh
Jan 29, 2026Jan 30, 2026
traded Jan 29, 2026
+1dSEC Form 4

Evidence

6
Farquhar ScottDirector, 10% Owner
TEAMAtlassian Corp
Open-market sale · 10b5-1 plan
SELL$65K
543 sh
Jan 29, 2026Jan 30, 2026
traded Jan 29, 2026
+1dSEC Form 4

Evidence

6
Farquhar ScottDirector, 10% Owner
TEAMAtlassian Corp
Open-market sale · 10b5-1 plan
SELL$141K
1,200 sh
Jan 29, 2026Jan 30, 2026
traded Jan 29, 2026
+1dSEC Form 4

Evidence

6
CM
Cannon-Brookes MichaelDirector, CEO, Co-Founder, 10% Owner
TEAMAtlassian Corp
Open-market sale · 10b5-1 plan
SELL$65K
543 sh
Jan 29, 2026Jan 30, 2026
traded Jan 29, 2026
+1dSEC Form 4

Evidence

6
CM
Cannon-Brookes MichaelDirector, CEO, Co-Founder, 10% Owner
TEAMAtlassian Corp
Open-market sale · 10b5-1 plan
SELL$141K
1,200 sh
Jan 29, 2026Jan 30, 2026
traded Jan 29, 2026
+1dSEC Form 4

Evidence

5
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
1,925 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

5
RP
Radovich PeterPRESIDENT AND COO
MIRMMirum Pharmaceuticals, Inc.
Grant or award
A—
25.1K sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
QJ
Quan JoanneCHIEF MEDICAL OFFICER
MIRMMirum Pharmaceuticals, Inc.
Grant or award
A—
11.8K sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
1,925 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

5
SI
Stefan Constantin IonelChief Technology Officer
AMPXAmprius Technologies, Inc.
Option exercise
M$55.8
90 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
BM
Brosius MarkSVP & Chief Mfg and Supply Cha
ISRGINTUITIVE SURGICAL INC
Grant or award
A—
2,702 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
SI
Stefan Constantin IonelChief Technology Officer
AMPXAmprius Technologies, Inc.
Option exercise
M—
39.6K sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
QJ
Quan JoanneCHIEF MEDICAL OFFICER
MIRMMirum Pharmaceuticals, Inc.
Grant or award
A—
20.0K sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
CL
Charlton Henry LEVP & Chief Commercial and Mkt
ISRGINTUITIVE SURGICAL INC
Grant or award
A—
7,182 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
HJ
Howe JolandaSVP, GLOBAL CONTROLLER
MIRMMirum Pharmaceuticals, Inc.
Grant or award
A—
7,680 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,859 sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC Form 4

Evidence

5
SI
Stefan Constantin IonelChief Technology Officer
AMPXAmprius Technologies, Inc.
Option exercise
M—
90 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
BM
Brosius MarkSVP & Chief Mfg and Supply Cha
ISRGINTUITIVE SURGICAL INC
Grant or award
A—
5,585 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
TJ
Twomey Cormac JEVP, Global Ops & Delivery
CNXCConcentrix Corp
Tax withholding
F$8,390
231 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
HJ
Howe JolandaSVP, GLOBAL CONTROLLER
MIRMMirum Pharmaceuticals, Inc.
Grant or award
A—
9,000 sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence

5
RP
Radovich PeterPRESIDENT AND COO
MIRMMirum Pharmaceuticals, Inc.
Grant or award
A—
16.3K sh
Jan 28, 2026Jan 30, 2026
traded Jan 28, 2026
+2dSEC Form 4

Evidence